Physician profile
James Amara
NPI 1114671880
$2,128.64
in general payments reported to CMS, 2019-2025
19 companies · $1,174 in 2025
The $1,174 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.01 · 2024: $931 · 2025: $1,174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,104 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,104.03 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $250.38 | 2024-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $236.34 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $185.88 | 2023-2025 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $165.67 | 2024-2025 | |
| Novo Nordisk INC | $156.23 | 2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $147.69 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $137.34 | 2024-2025 | Jynarque |
| Ardelyx, INC. | $134.50 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $130.73 | 2024-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $124.01 | 2024-2025 | Tarpeyo |
| Astrazeneca Pharmaceuticals LP | $123.32 | 2024-2025 | Farxiga |
| Amgen INC. | $79.04 | 2025 | Krystexxa |
| Fresenius USA Marketing, INC. | $78.12 | 2024-2025 | Velphoro, Velphoro |
| Aurinia Pharma U.S., INC. | $48.52 | 2024 | Lupkynis |
| Glaxosmithkline, LLC. | $34.73 | 2024-2025 | Jesduvroq, Shingrix |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $31.02 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.97 | 2024 | Jynarque |
| Apellis Pharmaceuticals, INC. | $24.88 | 2025 | Empaveli |
| Travere Therapeutics, INC. | $15.27 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Amara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.